NTI 1.89% 5.4¢ neurotech international limited

Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint, page-8

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 8,482 Posts.
    lightbulb Created with Sketch. 1210
    Pretty sure they are going for TGA Approval for the Autism Spectrum Disorder Treatment,
    TGA is like the Aussie version of FDA Approval,
    And should be rather straight forward seeing other cannabis products
    have already been approved here.

    But yeah fairly sure it is FDA for the others.
    Generally FDA Approval is done after Phase III.
    Although their have also been cannabis products approved there,
    Which should make it easier as well.

    Also as @miskamouse recently posted the US may be moving Cannabis to Schedule III,
    Which some legal experts have suggested doctors and dispensaries will be able to dispense Cannabis products direct to patients without a prescription of FDA Approval.

    This could make it a lot easier for NTI if it occurs....
    Last edited by $$$$$$$$: 02/05/24
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
5.4¢
Change
0.001(1.89%)
Mkt cap ! $55.86M
Open High Low Value Volume
5.3¢ 5.5¢ 5.3¢ $47.86K 886.4K

Buyers (Bids)

No. Vol. Price($)
1 248424 5.4¢
 

Sellers (Offers)

Price($) Vol. No.
5.5¢ 268385 2
View Market Depth
Last trade - 16.10pm 11/11/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.